Captopril Reduces the Potential Proteinuric Effect of Exogenous Growth Hormone in Adriamycin Nephrosis (An). + 2176

Growth Hormone (GH) is being increasingly used for growth failure associated with renal disease. Over time, however, GH, by increasing glomerular perfusion, might compromise residual renal function. Since Captopril (C) decreases glomerular perfusion and has been shown to decrease protein excretion in the presence of renal disease, we tested its potential protective effect in GH treated rats with AN, a model of heavy proteinuria and glomerular injury. We induced AN in Sprague-Dawley rats ≈125 g body weight with Adriamycin given as an initial dose of 5 mg/kg and as a subsequent dose 3 weeks later of 2 mg/kg. Rats with AN received either saline (S), GH (0.2 mg/day SC 5 days/week) alone, or GH + C (100 mg/kg/day PO). At 40 and 76 days after induction of AN, proteinuria was reduced in AN rats receiving growth hormone + captopril compared to those receiving either saline or GH alone(p<0.05). Serum cholesterol (mg/dl) was lower (p < 0.05) in AN + GH + C(211 ± 47) than in AN + S (521 ± 27) and AN + GH (412 ± 37) treated rats. We conclude that large doses of growth hormone increase proteinuria in rats with Adriamycin Nephrosis and this effect is partially ameliorated by captopril. (Funded by Genentech, Inc).Table

RENAL FUNCTION (mean...

Section Description

Abstracts and Program Outline

May 6 - 10, 1996; Monday - Friday

Sheraton Washington & Omni Shoreham Hotels; Washington, DC

Presentation Codes:

† POSTER SESSION

▴ POSTER SYMPOSIUM

• PLATFORM SESSION

NEPHROLOGY